2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jia Ruan, MD, PhD, discusses some of the unanswered questions regarding optimizing treatment selection in patients with mantle cell lymphoma.
Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses some of the unanswered questions regarding optimizing treatment selection in patients with mantle cell lymphoma (MCL).
Head-to-head data are needed to compare the efficacy and safety of available treatment options in MCL, says Ruan.
Additionally, some research efforts should be directed toward evaluating combinations with novel agents and chemotherapy that may improve patient outcomes, explains Ruan.
Identifying predictive biomarkers of response to treatment and risk of relapse is critical to better inform treatment selection, says Ruan.
Finally, determining the role of minimal residual disease assessment and how it may influence treatment intensification is a remaining question in this space, Ruan concludes.